Japan's Eisai eyes blood test for Alzheimer's drug eligibility
TOKYO -- Japanese pharmaceutical company Eisai is developing a blood test to determine whether patients with Alzheimer's disease can benefit from lecanemab, marking another step in its efforts to expand its dementia treatment and care business.